BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi T, Takeuchi A, Nishiyama H, Eto M. Current status and future perspectives of immunotherapy against urothelial and kidney cancer. Jpn J Clin Oncol 2021:hyab121. [PMID: 34389866 DOI: 10.1093/jjco/hyab121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kunitoh H. Message from the Editor-in-Chief. Jpn J Clin Oncol 2023;53:1-3. [PMID: 36611291 DOI: 10.1093/jjco/hyac196] [Reference Citation Analysis]
2 Feng H, Kou X, Tang Z, Li L, V E S. FYU-Net: A Cascading Segmentation Network for Kidney Tumor Medical Imaging. Computational and Mathematical Methods in Medicine 2022;2022:1-10. [DOI: 10.1155/2022/4792532] [Reference Citation Analysis]
3 Sakatani T, Kita Y, Fujimoto M, Sano T, Hamada A, Nakamura K, Takada H, Goto T, Sawada A, Akamatsu S, Kobayashi T. IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab. Cancers (Basel) 2022;14:263. [PMID: 35053427 DOI: 10.3390/cancers14020263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Kunitoh H. Message from the Editor-in-Chief. Jpn J Clin Oncol 2022;52:1-2. [PMID: 34978327 DOI: 10.1093/jjco/hyab190] [Reference Citation Analysis]